Europe Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Europe organoids market is projected to grow significantly, reaching approximately US$ 5,016.03 million by 2031, up from US$ 1,018.12 million in 2023, reflecting a compound annual growth rate (CAGR) of 22.1% during this period.

Executive Summary and Market Analysis

The organoids market in Europe is divided into several regions, including Germany, France, Italy, the UK, Spain, and the Rest of Europe. The growth of this market is driven by several factors, including the increasing demand for tissue engineering and organ transplantation, the rising use of organoids in disease modeling, gene mutation studies, and tumor modeling, as well as heightened research activities related to organoids. Additionally, the influx of funding and investments from both public and private sectors is expected to create promising opportunities for market expansion in the coming years.

Market Segmentation Analysis

The Europe organoids market can be analyzed through various segments, including type, application, source, offering, and method:

Type: The market is categorized into organoids derived from the intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2023, the intestine organoids held the largest market share.
Application: The applications of organoids include developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery, and personalized medicine. Developmental biology applications dominated the market in 2023.
Source: The market is divided into organoids sourced from pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells holding a larger market share in 2023.
Offering: This segment includes instruments, consumables, and services, with consumables leading the market in 2023. Instruments are further divided into devices and equipment, while consumables include sensors and other items.
Method: The methods used in organoid production include micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion techniques, with the hanging drop method being the most prevalent in 2023.

Market Outlook

The demand for innovative drugs is accelerating the pace of drug discovery and research. As of 2021, there were approximately 384,288 clinical trial studies registered on ClinicalTrials.gov. A survey by HUB indicates that organoids can enhance the cost-effectiveness of expensive drugs by identifying patients unlikely to benefit from certain treatments, thus optimizing clinical trial designs. Organoids are not only utilized in cancer research but also in studies related to cystic fibrosis, polycystic kidney disease, microcephaly, and infections affecting the gut and airways. They can replicate organ properties, including structure and function, and can restore the genetic and epigenetic states of tissues, making them suitable for gene editing applications.

Recent studies have shown promising results in combining CRISPR-Cas9 technology with organoids, leading to advancements in treatments for conditions like cystic fibrosis. For example, a 2020 study highlighted a biobank of cystic fibrosis intestinal organoids from 664 patients, with a significant portion potentially benefiting from gene editing. However, challenges remain regarding the efficiency and success rates of gene-edited organoids, necessitating further research into their safety, stability, and functionality. The ongoing focus on drug discovery in previously unexplored medical areas presents substantial growth opportunities for the organoids market.

Country Insights

The Europe organoids market is further analyzed by country, with Germany leading the market in 2023. Germany is recognized for its robust biotechnology sector, characterized by high-quality products and the presence of major biotechnology firms. For instance, researchers at the Max Planck Institute for Molecular Biomedicine in Münster have made strides in automating the production of midbrain organoids, enhancing the potential for large-scale research and high-throughput drug discovery.

The demand for tissue engineering and organ transplantation in Germany is expected to drive market growth, as there is a significant gap between organ supply and demand. In 2021, only 2,905 organs were donated, while the demand on the transplant list reached 8,730. Human organoids are increasingly being used to study diseases and have the potential to serve as transplantable organs, mitigating issues related to tissue rejection and the risk of introducing animal pathogens.

Company Profiles

Key players in the organoids market include STEMCELL Technologies Inc., Molecular Devices, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, Thermo Fisher Scientific, Corning, Merck KGaA, InSphero, ACRO Biosystems, Bio-Techne, SUN bioscience, ORGANOID SCIENCES, Crown Bioscience, Sartorius AG, 3D Biotek, Prellis Biologics, 3Dnamics, and Cellesce. These companies are pursuing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe organoids market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more